RIVM European Reference Lab for vector-borne infections The European Commission (EC) has designated RIVM as the current European Reference Lab (EURL) for vector-borne viral pathogens.
Menno de Jong appointed director of RIVM Centre for Infectious Disease Control Starting 1 May 2024, Professor Menno de Jong will take on the role of director of RIVM’s Centre for Infectious Disease Control (CIb) . He succeeds Jaap van Dissel, who is retiring in April 2024.
Many serious cases of whooping cough among newborn babies in the Netherlands The number of newborn babies in the Netherlands who are seriously ill due to whooping cough has been increasingly rapidly in recent weeks. About 110 confirmed cases of whooping cough are now being diagnosed every week among children in the Netherlands, including nearly 20 infants.
RIVM identifies three major challenges for public health and healthcare in period to 2050 The Dutch public health and healthcare will face three crucial challenges in the period to 2050. This is according to RIVM’s preview of the Dutch Public Health Foresight Study 2024.
Direct link between Tata Steel emissions, nuisance and risk of disease The current level of emissions from the Tata Steel site is putting people who live in the IJmond region at an elevated risk of disease. The greatest benefits to public health in the region can be achieved by reducing nuisance caused by and exposure to Tata Steel emissions. This is the outcome of a study conducted by RIVM.
Mercury in Groningen’s natural gas not harmful to health Mercury can be naturally present in natural gas. This mercury can end up in your home, especially if you use a natural gas cooker. In 2014, the Nederlandse Aardolie Maatschappij (NAM) calculated exposure to mercury at daily peak moments.
More than two million invitations to get vaccinated against HPV in 2023 In early 2023, 1.3 million young adults will receive an invitation to get vaccinated against the human papillomavirus (HPV). This group comprises around 900,000 men and 400,000 women between the ages of 19 and 27.
Vaccination coverage increases for second consecutive year, by 10% for HPV The percentage of children receiving vaccinations from the National Immunisation Programme rose again last year. Another striking note is the 10% increase in HPV vaccination, rising to 63%.
COVID-19 consequences impact vulnerable groups more in the long term The effects of the corona crisis have a greater impact on vulnerable groups in society, such as lower-educated adults, young people, the elderly and people with underlying health problems.
Report on the developments of the National Immunisation Programme: national immunisation coverage increased slightly for the first time in five years National immunisation coverage has increased for the first time in five years, for almost all vaccinations. For children born in 2017, vaccination coverage against mumps, measles and rubella (MMR) increased by 0.7% to 93.6%.